BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12930314)

  • 21. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions.
    Gamerdinger U; Teigler-Schlegel A; Pils S; Bruch J; Viehmann S; Keller M; Jauch A; Harbott J
    Genes Chromosomes Cancer; 2003 Mar; 36(3):261-72. PubMed ID: 12557226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complex translocation (8;12;21): a new variant of t(8;21) in acute myeloid leukemia.
    Farra C; Awwad J; Valent A; Lozach F; Bernheim A
    Cancer Genet Cytogenet; 2004 Dec; 155(2):138-42. PubMed ID: 15571799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
    Guo BY; Wang Y; Li J; Li CF; Feng XQ; Zheng MC; Liu SX; Yang LH; Jiang H; Xu HG; He XL; Wen H
    Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):881-888. PubMed ID: 37803854
    [No Abstract]   [Full Text] [Related]  

  • 26. Translocation (8;17;15;21)(q22;q23;q15;q22) in acute myeloid leukemia (M2). a four-way variant of t(8;21).
    Vieira L; Oliveira V; Ambrósio AP; Marques B; Pereira AM; Hagemeijer A; Boavida MG
    Cancer Genet Cytogenet; 2001 Jul; 128(2):104-7. PubMed ID: 11463447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. t(8;21;14)(q22;q22;q24) is a novel variant of t(8;21) with chimeric transcripts of AML1-ETO in acute myelogenous leukemia.
    Ishida F; Ueno M; Tanaka H; Makishima H; Suzawa K; Hosaka S; Hidaka E; Ishikawa M; Yamauchi K; Kitano K; Kiyosawa K
    Cancer Genet Cytogenet; 2002 Jan; 132(2):133-5. PubMed ID: 11850074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML.
    Mitterbauer M; Kusec R; Schwarzinger I; Haas OA; Lechner K; Jaeger U
    Ann Hematol; 1998; 76(3-4):139-43. PubMed ID: 9619731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.
    Yin JA; Frost L
    Curr Oncol Rep; 2003 Sep; 5(5):399-404. PubMed ID: 12895392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptome Profiling of Pediatric Core Binding Factor AML.
    Hsu CH; Nguyen C; Yan C; Ries RE; Chen QR; Hu Y; Ostronoff F; Stirewalt DL; Komatsoulis G; Levy S; Meerzaman D; Meshinchi S
    PLoS One; 2015; 10(9):e0138782. PubMed ID: 26397705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translocation(8;20;21)(q22;q13;q22) in acute myeloblastic leukemia with maturation: a variant form of t(8;21).
    Wong KF; Kwong YL; So CC
    Cancer Genet Cytogenet; 1998 Feb; 101(1):39-41. PubMed ID: 9460498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
    Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
    Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia.
    Wattjes MP; Krauter J; Nagel S; Heidenreich O; Ganser A; Heil G
    Leukemia; 2000 Feb; 14(2):329-35. PubMed ID: 10673753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Harada M; Niho Y
    Leuk Lymphoma; 1997 Mar; 25(1-2):69-75. PubMed ID: 9130615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay.
    Muto A; Mori S; Matsushita H; Awaya N; Ueno H; Takayama N; Okamoto S; Kizaki M; Ikeda Y
    Br J Haematol; 1996 Oct; 95(1):85-94. PubMed ID: 8857943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
    Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
    Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.